Literature DB >> 11127463

Sudden death in hypertrophic cardiomyopathy: identification of high risk patients.

P M Elliott1, J Poloniecki, S Dickie, S Sharma, L Monserrat, A Varnava, N G Mahon, W J McKenna.   

Abstract

OBJECTIVES: We sought to identify patients with hypertrophic cardiomyopathy (HCM) at high risk of sudden death (SD).
BACKGROUND: Relatively low mortality rates in HCM make conventional analysis of multiple clinical risk markers for SD problematic. This study used a referral center registry to investigate a smaller number of generally accepted noninvasive risk markers.
METHODS: We studied 368 patients (14 to 65 years old, 239 males) with HCM. There were five variables: nonsustained ventricular tachycardia (NSVT), syncope, exercise blood pressure response (BPR), family history of sudden death (FHSD) and left ventricular wall thickness (LVWT).
RESULTS: During follow-up (3.6+/-2.5 years [range 2 days to 9.6 years]), 36 patients (9.8%) died, 22 of them suddenly. Two patients received heart transplants. The six-year SD-free survival rate was 91% (95% confidence interval [CI] 87% to 95%). In the Cox model, there was a significant pairwise interaction between FHSD and syncope (p = 0.01), and these were subsequently considered together. The multivariate SD risk ratios (with 95% CIs) were 1.8 for BPR (0.7 to 4.4) (p = 0.22); 5.3 for FHSD and syncope (1.9 to 14.9) (p = 0.002); 1.9 for NSVT (0.7 to 5.0) (p = 0.18) and 2.9 for LVWT (1.1 to 7.1) (p = 0.03). Patients with no risk factors (n = 203) had an estimated six-year SD-free survival rate of 95% (95% CI 91% to 99%). The corresponding six-year estimates (with 95% CIs) for one (n = 122), two (n = 36) and three (n = 7) risk factors were 93% (87% to 99%), 82% (67% to 96%) and 36% (0% to 75%), respectively. Patients with two or more risk factors had a lower six-year SD survival rate (95% CI) compared with patients with one or no risk factors (72% [56% to 88%] vs. 94% [91% to 98%]) (p = 0.0001).
CONCLUSIONS: This study demonstrates that patients with multiple risk factors have a substantially increased risk of SD sufficient to warrant consideration for prophylactic therapy.

Entities:  

Mesh:

Year:  2000        PMID: 11127463     DOI: 10.1016/s0735-1097(00)01003-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  176 in total

Review 1.  Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death.

Authors:  William J McKenna; Elijah R Behr
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

Review 2.  The role of magnetic resonance imaging in hypertrophic cardiomyopathy.

Authors:  Edward T D Hoey; Mohamed Elassaly; Arul Ganeshan; Richard W Watkin; Helen Simpson
Journal:  Quant Imaging Med Surg       Date:  2014-10

3.  On predictors of sudden cardiac death in hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

4.  Contemporary considerations for risk stratification, sudden death and prevention in hypertrophic cardiomyopathy.

Authors:  B J Maron
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

Review 5.  Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy.

Authors:  Michael P Frenneaux
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

Review 6.  The MOGE(S) classification for cardiomyopathies: current status and future outlook.

Authors:  Julian G Westphal; Angelos G Rigopoulos; Constantinos Bakogiannis; Sarah E Ludwig; Sophie Mavrogeni; Boris Bigalke; Torsten Doenst; Matthias Pauschinger; Carsten Tschöpe; P Christian Schulze; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

7.  Evaluation of coronary artery disease and cardiac morphology and function in patients with hypertrophic cardiomyopathy, using cardiac computed tomography.

Authors:  Satoshi Okayama; Tsunenari Soeda; Rika Kawakami; Yasuhiro Takami; Satoshi Somekawa; Tomoya Ueda; Yu Sugawara; Takaki Matsumoto; Ji Hee Sung; Taku Nishida; Shiro Uemura; Yoshihiko Saito
Journal:  Heart Vessels       Date:  2013-12-11       Impact factor: 2.037

Review 8.  State-of-the-art narrative review: multimodality imaging in electrophysiology and cardiac device therapies.

Authors:  Balint Laczay; Divyang Patel; Richard Grimm; Bo Xu
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

9.  Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis.

Authors:  A Woo; H Rakowski; J C Liew; M-S Zhao; C-C Liew; T G Parker; M Zeller; E D Wigle; M J Sole
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

Review 10.  Management of hypertrophic cardiomyopathy in children.

Authors:  Hubert Seggewiss; Angelos Rigopoulos
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.